Share a DM level mcq question with 4 options for a pulmonary medicine

Share a DM level mcq question with 4 options for a pulmonary medicine resident Topic of mcq is tropical pulmonary eosinophilia

Reading File

Searching sources...

Finding Sources

Searching PubMed

"tropical pulmonary eosinophilia" diagnosis treatment

Reading File

I now have excellent source material from Murray & Nadel's Textbook of Respiratory Medicine and Fishman's Pulmonary Diseases and Disorders. Here is a DM-level MCQ:

DM Pulmonary Medicine - MCQ

A 32-year-old man from Tamil Nadu presents with a 3-month history of nocturnal paroxysmal cough, exertional dyspnea, and low-grade fever. Examination reveals bilateral wheeze. Investigations show: absolute eosinophil count 5,800/μL (5.8 × 10⁹/L), serum IgE 6,400 IU/mL, strongly positive antifilarial IgG, and negative blood microfilaria smear. HRCT chest shows bilateral reticulonodular opacities. He is started on diethylcarbamazine (DEC) 6 mg/kg/day for 3 weeks with significant symptomatic improvement. However, at 18-month follow-up, he reports recurrent dyspnea on exertion and spirometry now shows an FVC of 68% predicted with FEV1/FVC of 0.82.

Which of the following best explains his current spirometric pattern and its pathological basis?

(A) Ongoing eosinophilic airway inflammation causing irreversible bronchoconstriction, representing a fixed obstructive defect from filarial antigen-driven remodeling

(B) Pulmonary fibrosis with histiocytic infiltration developing as a consequence of inadequately treated or late/recurrent TPE, resulting in a restrictive ventilatory defect

(C) Development of allergic bronchopulmonary aspergillosis (ABPA) triggered by the prior eosinophilic milieu, causing central bronchiectasis with mixed obstruction

(D) DEC-induced obliterative bronchiolitis causing air-trapping and a pseudo-restrictive pattern on spirometry

Answer: (B)

Explanation:

Cases of TPE left untreated for 5 years or more - or with inadequate treatment - eventually develop pulmonary fibrosis with histiocytic infiltration. This results in a restrictive ventilatory defect (reduced FVC, normal or elevated FEV1/FVC), which is exactly the pattern seen here (FVC 68%, FEV1/FVC 0.82).

The restrictive fibrotic end-stage is a well-recognized long-term complication of chronic or recurrent TPE, caused by persistent localized eosinophil degranulation in the lung vasculature and interstitium even after the acute phase resolves. Clinically important points tested here:

Why (A) is wrong: TPE can cause a reversible obstructive defect acutely (wheezing, hyperinflation), but the classic late complication is restrictive, not obstructive
Why (C) is wrong: ABPA is caused by Aspergillus fumigatus sensitization, not filarial antigens; the high IgE here is filarial in origin, and there is no mucoid impaction or central bronchiectasis described
Why (D) is wrong: DEC is not associated with obliterative bronchiolitis; it is the definitive treatment for TPE

Key DM-level teaching point: Murray & Nadel notes that both a reversible obstructive defect (early, from bronchospasm) AND a restrictive defect (late, from fibrosis) can occur in TPE - distinguishing the chronological stage and the mechanism is the discriminating knowledge expected at the DM level.

Source: Murray & Nadel's Textbook of Respiratory Medicine, Chapter 58 - Tropical Pulmonary Eosinophilia (lines 2064-2066); Fishman's Pulmonary Diseases and Disorders, Chapter 71

IMG_9409.jpg

Create a poster .. Keep the content same

The image shows handwritten notes on TPE Management. Let me create a clean poster with exactly that content.

Generating Image

A clean medical education poster titled "TPE Management" (Tropical Pulmonary Eosinophilia). The poster has a professional clinical style with a white background and navy/dark blue accents. Content organized clearly: TITLE: "TPE Management" in bold dark blue at top with an underline Section 1 in bold: "D.O.C — Diethylcarbamazine (DEC)" Bullet points below: • 6 mg/kg/day — Orally, in 3 divided doses • Duration: 14–21 days (highlighted in a bordered box) • For a 50 kg adult: Total dose = 300 mg → 100 mg TID (shown with an arrow, both values in rounded banner/ribbon shapes) Clean typography, medical poster layout, no extra decoration, all text clearly readable.

Here's the clean poster version of your handwritten notes on TPE Management, with all content preserved:

D.O.C: Diethylcarbamazine (DEC)
Dose: 6 mg/kg/day orally in 3 divided doses
Duration: 14-21 days
For a 50 kg adult: Total 300 mg → 100 mg TID

Can u make the poster more colourful and attractive

Generating Image

A vibrant, colorful medical education poster titled "TPE Management" (Tropical Pulmonary Eosinophilia) for pulmonary medicine residents. Bold, eye-catching design with a bright gradient background (deep teal to purple). TITLE at top: "TPE Management" in large white bold font with a bright yellow underline glow effect, subtitle "Tropical Pulmonary Eosinophilia" in smaller white italic text below title. Content in bright colored cards/sections: 1. A bright coral/orange rounded card labeled "D.O.C" with a star badge, containing white text: "Diethylcarbamazine (DEC)" 2. A bright sky-blue rounded card with a pill icon: "6 mg/kg/day — Orally" in bold white text 3. A lime-green rounded card with a clock icon: "3 Divided Doses" in bold white text 4. A golden-yellow highlighted box with bold border: "Duration: 14 – 21 Days" 5. A pink/magenta section titled "For 50 kg Adult:" with an arrow graphic: - Left bubble in purple: "300 mg/day Total" - Arrow → - Right bubble in bright orange: "100 mg TID" All cards have drop shadows, rounded corners, bright contrasting colors. Fun medical infographic style, professional yet vibrant. White icons next to each point. Clean readable fonts throughout.

Here's the vibrant, colourful version! It features:

Gradient background (teal to purple)
Colour-coded cards for each key point - coral, sky-blue, lime-green, golden, and magenta
Arrow graphic clearly showing 300 mg/day → 100 mg TID for a 50 kg adult
Bold, easy-to-read fonts throughout

Let me know if you'd like any changes to the colours, layout, or content!

This is a shared conversation. Sign in to Orris to start your own chat.